Filtered By:
Specialty: General Medicine
Condition: Atrial Fibrillation

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 1009 results found since Jan 2013.

The changing use of anticoagulants in New Zealand
CONCLUSIONS: The introduction of the DOACs was expected to reduce the use of warfarin. However, the rapid rise in DOAC use was not predicted. The increase is most likely in patients with atrial fibrillation with the positive benefit of reducing the incidence of embolic stroke. However, having a high proportion of the elderly population (15% of people over 75-years) on anticoagulants has implications for the health sector, making hospital admissions and surgery more complex.PMID:35728215
Source: New Zealand Medical Journal - June 21, 2022 Category: General Medicine Authors: Paul Harper Alison Chang Matt Stephens Source Type: research

Use of Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke
To the Editor A recent study examined the safety of intravenous alteplase in patients taking NOACs within 7 days of acute ischemic stroke. Although the authors paired GWTG-Stroke registry data with data from the ARAMIS registry, the time of last NOAC dose was known in only 2% of patients in this study. Moreover, patients taking NOACs within 48 hours of intravenous alteplase experienced a higher rate of symptomatic intracranial hemorrhage compared with the overall NOAC population (8% vs 3.7%), suggesting that alteplase should be avoided within 48 hours of NOAC administration until more comprehensive data are available. A re...
Source: JAMA - June 21, 2022 Category: General Medicine Source Type: research

Detection of paroxysmal atrial fibrillation in 994 patients with a cerebrovascular event by intermittent 21-day ECG-monitoring and 7-day continuous Holter-recording
CONCLUSIONS: The two screening approaches had a similar yield of arrhythmia, in spite of the group with intermittent monitoring having a more favorable clinical profile. A positive screening was highly predictive of AF in ECG during the follow-up.PMID:35722185 | PMC:PMC9169544 | DOI:10.48101/ujms.v127.8318
Source: Upsala Journal of Medical Sciences - June 20, 2022 Category: General Medicine Authors: Johanna Pennlert M årten Rosenqvist Milos Kesek Source Type: research

Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
Introduction Rivaroxaban is one of the most commonly used non-vitamin K antagonists for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual exposures exist for Asian and non-Asian populations, and dose selection is different for Japanese and non-Japanese subjects. Few studies have investigated the pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in Chinese patients and provided a solid reference for dose selection and individualised therapy. Methods and analysis This is a single-centre prospective study. Rivaroxaban-treated Chinese NVAF patients will be recruited ...
Source: BMJ Open - June 3, 2022 Category: General Medicine Authors: Liu, X.-Q., Zhang, Y.-F., Ding, H.-Y., Yan, M.-M., Zhong, M.-K., Ma, C.-L. Tags: Open access, Pharmacology and therapeutics Source Type: research

Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case-control analyses from UK primary care
Conclusions Dosing appropriateness in NVAF was not associated with a significant difference in IS/SE risk or increase in ICB risk versus warfarin. These findings may reflect residual confounding and biases that were difficult to control, as also seen in other observational studies. They should, therefore, be interpreted with caution, and prescribers should adhere to the dosing instructions in the respective Summary of Product Characteristics. Further studies on this topic from real-world populations are needed.
Source: BMJ Open - June 2, 2022 Category: General Medicine Authors: Gonzalez-Perez, A., Roberts, L., Vora, P., Saez, M. E., Brobert, G., Fatoba, S., Garcia Rodriguez, L. A. Tags: Open access, Cardiovascular medicine Source Type: research